Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PLASMA-LYTE R IN PLASTIC CONTAINER vs ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Plasma-Lyte R provides electrolytes and water to maintain or restore fluid balance, with bicarbonate precursors (acetate, gluconate) to buffer metabolic acidosis.
Isolyte E in Dextrose 5% provides fluid, electrolytes, and calories. Dextrose is metabolized to carbon dioxide and water, yielding energy. Electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate) maintain acid-base balance and osmotic pressure.
Fluid and electrolyte replacement for maintenance or restoration,Treatment of mild to moderate metabolic acidosis
FDA-approved: For intravenous administration as a source of water, electrolytes, and calories in patients requiring fluid and electrolyte replacement.,Off-label: Not typically used off-label; primarily for maintenance or replacement therapy.
Intravenous infusion at a rate of 25-50 m L/kg body weight per 24 hours, adjusted for fluid and electrolyte needs. Typical adult maintenance dose: 1-2 L/day.
Intravenous infusion; typical adult dose is 1000-2000 m L per day (30 m L/kg/day) adjusted for fluid and electrolyte needs; rate based on clinical status.
Not applicable (Plasma-Lyte R components are endogenous electrolytes and water; administered crystalloid redistributes rapidly; half-life of approximately 20-30 minutes for volume expansion due to renal excretion and redistribution into interstitial space)
Not applicable; components are endogenous substances. Dextrose half-life ~15-20 min after infusion; electrolytes distribute and are cleared renally with half-lives dependent on renal function.
Not metabolized; acetate and gluconate are metabolized to bicarbonate in the liver and peripheral tissues.
Dextrose undergoes glycolysis and the citric acid cycle; electrolytes are not metabolized but are excreted or incorporated into body pools.
Renal: >90% (electrolytes and water); Biliary/fecal: negligible (<5%)
ISOLYTE E in Dextrose 5% is a balanced electrolyte solution with glucose. Electrolytes are primarily excreted renally; water and dextrose are metabolized. Biliary/fecal excretion is negligible. Dextrose is metabolized to CO2 and water.
Minimal (<5%); ions remain free in solution
None for electrolytes and dextrose; sodium, potassium, chloride, magnesium, acetate, and gluconate are free ions in solution.
Approximately 0.25-0.3 L/kg (limited to extracellular fluid compartment; distributes primarily in plasma and interstitial fluid)
Sodium and chloride distribute primarily in extracellular fluid (~0.2 L/kg). Dextrose distributes in total body water (~0.6 L/kg). Potassium distributes in intracellular fluid (~0.6 L/kg after equilibration).
Intravenous: 100%
100% intravenous; not administered by other routes.
Contraindicated in severe renal impairment (creatinine clearance < 30 m L/min) due to risk of hyperkalemia and fluid overload. For mild-to-moderate impairment (Cr Cl 30-89 m L/min), reduce infusion rate by 25-50% and monitor serum potassium.
In renal impairment (e GFR < 30 m L/min/1.73m²), reduce total volume to 500-1000 m L/day with careful monitoring of potassium, sodium, and glucose; avoid if hyperkalemia or fluid overload.
Child-Pugh Class A: No adjustment. Child-Pugh B: Reduce infusion rate by 25% and monitor for fluid overload. Child-Pugh C: Avoid use due to risk of exacerbating ascites and electrolyte imbalances.
No specific dose adjustment for Child-Pugh class; monitor for fluid overload and electrolyte imbalances; in severe hepatic impairment, reduce volume to 500-1000 m L/day.
Weight-based dosing: 20-100 m L/kg/day as a continuous infusion, with rate not exceeding 50 m L/kg/hour. Adjust based on hydration status, serum electrolytes, and renal function.
Weight-based: 20-50 m L/kg/day for maintenance; neonates and infants: 100-150 m L/kg/day; adjust based on glucose, electrolytes, and hydration status; maximum rate 4 m L/kg/hour for neonates.
Initiate at low end of dosing range (e.g., 25-30 m L/kg/day) due to age-related renal decline and increased risk of fluid overload. Monitor serum potassium, creatinine, and fluid balance closely.
Start with lower volumes (500-1000 m L/day) due to decreased renal function and risk of fluid overload; monitor serum electrolytes, glucose, and central venous pressure.
None.
Not applicable; no FDA boxed warning exists for this product.
Use with caution in patients with heart failure, renal impairment, or conditions with sodium retention,Monitor serum electrolytes and fluid balance,Risk of hypervolemia,Do not use if solution contains precipitate or if container is damaged
Monitor serum electrolytes, fluid balance, and glucose levels; avoid fluid overload in patients with cardiac or renal impairment; risk of hyperglycemia in diabetic patients; use with caution in patients with metabolic alkalosis or hypokalemia.
Hypernatremia,Hyperchloremia,Metabolic alkalosis,Severe renal impairment with oliguria,Hypersensitivity to any component
Hypersensitivity to any component; clinically significant hyperglycemia; severe metabolic acidosis; hyperkalemia (for potassium-containing formulations); hypermagnesemia; fluid overload conditions.
No known food interactions. However, patients on a sodium- or potassium-restricted diet should consult their physician before receiving this solution.
No specific food interactions known. Monitor electrolyte intake in patients with electrolyte imbalances.
No evidence of teratogenicity. Plasma-Lyte R is an isotonic crystalloid solution; components (sodium, potassium, magnesium, chloride, acetate, gluconate) are physiological ions. No fetal risk identified in any trimester when used as indicated.
ISOLYTE E in Dextrose 5% is an intravenous electrolyte and carbohydrate solution. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been conducted. Dextrose and electrolytes are considered essential nutrients and are generally safe when used as indicated. However, administration during labor and delivery may cause fluid and electrolyte imbalances. First trimester risks are theoretical; second and third trimesters may involve risks of maternal hyperglycemia and fetal hyperinsulinemia if dextrose infusion is excessive. No specific teratogenicity reported.
Compatible with breastfeeding. The components are normal blood constituents; no excretion into milk expected. M/P ratio not applicable; no risk to nursing infant.
Dextrose and electrolytes are normal constituents of human milk. Following intravenous administration, concentrations in milk are expected to parallel maternal plasma levels. No specific M/P ratio is available. Use during breastfeeding is considered compatible; however, monitor for adverse effects in the infant such as electrolyte imbalance or hyperglycemia if maternal infusion is prolonged or high volume.
No dose adjustment required. Pregnancy does not alter pharmacokinetics of crystalloid solutions; administer based on clinical need for fluid and electrolyte replacement.
Pregnancy induces increased plasma volume and glomerular filtration rate, potentially diluting electrolytes and altering glucose metabolism. Dose adjustments may be required: consider lower dextrose infusion rates to avoid maternal hyperglycemia and fetal hyperinsulinemia. Monitor electrolytes closely; adjust potassium and magnesium supplementation as needed. No specific dose adjustment is universally recommended; individualize based on maternal weight, clinical status, and monitoring results.
Plasma-Lyte R is an isotonic crystalloid solution used for fluid and electrolyte resuscitation. It contains acetate and gluconate as buffers, which may be preferable in patients with lactic acidosis or hepatic dysfunction. Rapid infusion can cause volume overload; monitor renal function and serum electrolytes. Not recommended for patients with preexisting hyperkalemia.
ISOLYTE E in DEXTROSE 5% is an isotonic crystalloid solution for IV administration. Contains electrolytes (Na, K, Mg, Cl, acetate, gluconate) and dextrose 5%. Use with caution in patients with renal impairment, heart failure, or hyperkalemia. Monitor serum electrolytes, blood glucose, and fluid balance. Not for use as a sole source of nutrition. Do not administer if solution is discolored or contains particulates.
Inform your healthcare provider if you have kidney problems, heart failure, or are on a sodium-restricted diet.,Report any signs of fluid overload, such as shortness of breath, swelling in the ankles or feet, or sudden weight gain.,This solution contains potassium; avoid potassium supplements or salt substitutes unless directed by your doctor.
Inform your healthcare provider about all medical conditions, especially kidney disease, heart failure, or diabetes.,Report any signs of allergic reaction such as rash, itching, or trouble breathing.,Tell your doctor if you experience swelling, shortness of breath, or irregular heartbeat.,This solution contains dextrose (sugar); monitor blood glucose if you have diabetes.,Do not use if the bag is damaged or solution is cloudy.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PLASMA-LYTE R IN PLASTIC CONTAINER vs ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER, answered by our medical review team.
PLASMA-LYTE R IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution that works by Plasma-Lyte R provides electrolytes and water to maintain or restore fluid balance, with bicarbonate precursors (acetate, gluconate) to buffer metabolic acidosis.. ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution with Dextrose that works by Isolyte E in Dextrose 5% provides fluid, electrolytes, and calories. Dextrose is metabolized to carbon dioxide and water, yielding energy. Electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate) maintain acid-base balance and osmotic pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PLASMA-LYTE R IN PLASTIC CONTAINER and ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PLASMA-LYTE R IN PLASTIC CONTAINER is: Intravenous infusion at a rate of 25-50 m L/kg body weight per 24 hours, adjusted for fluid and electrolyte needs. Typical adult maintenance dose: 1-2 L/day.. The standard adult dose of ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion; typical adult dose is 1000-2000 m L per day (30 m L/kg/day) adjusted for fluid and electrolyte needs; rate based on clinical status.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PLASMA-LYTE R IN PLASTIC CONTAINER and ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PLASMA-LYTE R IN PLASTIC CONTAINER is classified as Category C. No evidence of teratogenicity. Plasma-Lyte R is an isotonic crystalloid solution; components (sodium, potassium, magnesium, chloride, acetate, gluconate) are physiological ions. No. ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. ISOLYTE E in Dextrose 5% is an intravenous electrolyte and carbohydrate solution. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies h. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.